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Abstract: Some drugs currently used to treat tics in pediatric
patients have drawbacks, including the risk of side effects. New
therapeutic options with better safety profiles are needed. Le-
vetiracetam is an antiepileptic drug with atypical mechanisms
of action that might be beneficial for this indication. We eval-
uated the effects of levetiracetam on motor and vocal tics,
behavior, and school performance in children and adolescents
with tics and Tourette syndrome (TS). Sixty patients, 18
years of age, with tics and TS were enrolled in this prospective,
open-label study. The initial starting dose of levetiracetam was
250 mg/day. The dosage was titrated over 3 weeks to 1,000 to
2,000 mg/day. Clinical outcomes were assessed with the Clin-
ical Global Impression Scale, Yale Global Tic Severity Scale,
and Revised Conners’ Parent Rating Scale. Behavior and
school performance were also recorded. All 60 patients showed
improvements based on all of the scales used, and 43 patients
improved with regard to behavior and school performance.
Levetiracetam was generally well tolerated. Three patients dis-
continued treatment because of exaggeration of preexisting
behavioral problems. Levetiracetam may be useful in treating
tics in children and adolescents. Given its established safety
profile, levetiracetam is a candidate for evaluation in a well-
controlled trial. © 2005 Movement Disorder Society
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Tics are a common movement disorder in children and
adolescents. As many as 10% of boys may experience
tics at some point during childhood; tics are less common
in girls.1–3 Both motor tics (e.g., involving the facial
muscles, neck, and upper limbs) and vocal tics (e.g.,
throat clearing, grunting, coughing, or cursing) occur in
patients with Tourette syndrome (TS). In addition, pa-
tients with TS often have comorbidities such as obses-
sive–compulsive disorder and attention deficit hyperac-
tivity disorder (ADHD).4
Although tics may spontaneously improve or resolve
over time, drug therapy should be considered for patients
whose symptoms interfere with their daily life. A major
goal of therapy for tics is to improve the patient’s quality
of life by minimizing the potential for social embarrass-
ment. Drugs used to treat TS include the neuroleptic
agents haloperidol, pimozide, and fluphenazine.5–7 How-
ever, the use of these drugs is associated with troubling
side effects. In one study, for example, only 12.5% (3 of
24) of patients with tics were able to continue their
haloperidol without interruption.8 Because of issues with
neuroleptic drugs, other agents that are less effective but
believed to be better tolerated are being evaluated for the
treatment of tics. Despite the evaluation of several drugs,
no single drug has emerged as an ideal therapy. Thus,
there continues to be a need for effective and safe agents
to treat tics.
Based on the proposed role of -aminobutyric acid
(GABA) in the dysfunction of the basal ganglia in pa-
tients with TS,7,9 GABAergic drugs may be a viable
therapeutic option to improve tics. GABAergic drugs
such as clonazepam and baclofen, for example, have
been evaluated.7,10 Levetiracetam is an antiepileptic drug
that may have atypical GABAergic effects.11 Levetirac-
etam inhibits the ability of zinc and beta carbolines to
interrupt chloride influx—an effect that enhances chlo-
ride ion influx at the GABA type A (GABA-A) receptor
complex.12 These mechanisms of action could produce a
beneficial effect in patients with TS. In addition, the
safety profile of levetiracetam is well established, and
there are some studies of the use of levetiracetam in
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children.13–19 Thus, levetiracetam may be a better-toler-
ated alternative to currently used therapies.
The effect of levetiracetam on motor and vocal tics
was studied in an open-label manner in a population of
children and adolescents with tics and TS. In addition,
the effects of levetiracetam therapy on measures of be-
havior and school performance were recorded.
PATIENTS AND METHODS
Patients
Sixty patients (18 years of age) with tics and TS who
were treated at the Oakwood Healthcare System in Mich-
igan were enrolled in a prospective, open-label study. All
patients met the DSM-IV criteria for tics and TS.20 All
patients were newly diagnosed and, thus, had not been
previously treated for TS. The period between diagnosis
and study entry was 1 to 2 months. Appropriate informed
consent was obtained for each patient.
Dosing and Administration
The initial dose of levetiracetam was 250 mg/day
(p.o.). The dosage was titrated over a 3-week period up
to 1,000 to 2,000 mg/day, based on response as well as
tolerability. The dosage was usually increased by 250 mg
every 5 to 7 days. Age and body weight were consider-
ations in dosing based on published information regard-
ing the use of levetiracetam in children.13,16 At the time
of this analysis, patients were treated with levetiracetam
for 1 year. No concomitant medications were used to
treat tics.
Measures of Clinical Efficacy
Clinical outcomes were assessed with the Clinical
Global Impression Scale (CGI), Yale Global Tic Severity
Scale (YGTSS), and Revised Conners’ Behavior Scales,
including the Revised Conners’ Teacher Rating Scale
(CTRS-R). Evaluations were completed at baseline and
3, 6, and 12 months after initiation of therapy.
The CGI is a seven-point scale based on all available
information concerning the adverse impact of tic behav-
ior on the patient’s life. The YGTSS consists of the
separate rating of severity for motor and vocal tics along
five discriminate dimensions. A scale of 0 to 5 is used for
each dimension, including number, frequency, intensity,
complexity, and interference. The summation of these
scores (0 to 50) produces a Total Tic Score (TTS). The
Tic Impairment Score (TIS), based on the impact of the
tic disorder on areas such as self-esteem, family life,
social acceptance, and school performance, is added to
the TTS to obtain the total YGTSS score.
The Revised Conners’ Behavior Scales assess problem
behaviors reported by teachers, parents, other caregivers,
and adolescent patients. The Revised Conners’ Parent
Rating Scale (CPRS-R) and the CTRS-R include scales
pertaining to ADHD behaviors, inattention, and hyper-
activity/impulsivity. The 27-item CPRS-R (known as the
short form or CPRS-R:S) includes five scales, and the
28-item CTRS-R (known as the short form or CTRS-
R:S) includes four scales. The Conner–Wells’ Adoles-
cent Self-Report Scale-Short version was used to assess
self-reports of problem behaviors.
Other assessments of behavior and school perfor-
mance were completed by reviewing report cards,
progress reports, and improvements in grade point aver-
age. Parent interviews were also used to evaluate the
behavior and school performance of the patients.
Statistical Analyses
Changes from baseline to 1 year after treatment on
scales of clinical outcomes were analyzed using SPSS v.
10.0 software (SPSS, Chicago, IL). Differences were
assessed using the two-tailed paired t test.
RESULTS
Demographic Characteristics
The mean age of patients enrolled in this trial was 12
years, with a range of 6 to 18 years of age. The patient
population was predominantly male, with 45 boys (75%)
and 15 girls (25%).
Dosing of Levetiracetam
Most patients (n  23) were treated with 1,000 mg/
day levetiracetam (Fig. 1). There were 2 patients who
were treated with 500 mg/day, 20 with 1,500 mg/day,
and 15 with 2,000 mg/day.
Clinical Improvement
All 60 patients showed significant clinical improve-
ments in their vocal and motor tics as determined by the
FIG. 1. Dosing of levetiracetam.
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YGTSS, TIS, TTS, and CGI scales (P  0.05; Figs.
2–5).
A total of 43 patients showed improvement in their
behavior and school performance as determined by the
CPRS-R (P  0.04) and the Conner–Wells’ Adolescent
Self-Report Scale-Short version (P  0.05). In addition,
grade point averages improved from 1.5  1.0 to 2.5 
0.5.
Safety and Tolerability of Levetiracetam Therapy
With regard to mean, aggressive, and impulsive be-
havior, 3 patients had baseline behavior or ADHD symp-
toms, or both. These 3 patients withdrew from the study
because of exaggeration of their behavior problems.
Somnolence was experienced by 4 patients. In 3 pa-
tients, this somnolence dissipated over time. In the fourth
patient, the dose of levetiracetam was reduced and ti-
trated more slowly. There were 2 patients who reported
asthenia and 5 reported headache.
DISCUSSION
Tics and TS can impair the quality of life of children
and adolescents because of social embarrassment and
symptoms that interfere with their daily functioning.
Thus, it is important to address these conditions, given
that they often occur during critical periods of learning
and development.
Several drugs have been evaluated for the treatment of
TS. Treatment with haloperidol results in improvement
in an estimated 70% to 80% of patients.6 However,
haloperidol is associated with potentially serious side
effects such as tardive dyskinesia. More recently intro-
duced atypical neuroleptics, including risperidone,
quetiapine, olanzapine, and clozapine, may have fewer or
different side effects but are still less than optimal. Chil-
dren may be more vulnerable to adverse effects of neu-
roleptic agents, including sedation, weight gain, and ex-
trapyramidal symptoms than adults.21
The -2 adrenergic agents clonidine and guanfacine
are also used to treat tic disorders.4,10 Although these
drugs may not be as effective as neuroleptic agents, their
side-effect profiles are preferable to those of neuroleptic
drugs. Several antidepressants,6 and other agents, such as
the opioid antagonist naloxone, have been used to treat
tics. None of these drugs has emerged as an ideal therapy
for TS, and new treatment options are being evaluated.
FIG. 4. Mean Total Tic Score at baseline and after treatment with
levetiracetam.
FIG. 5. Mean Clinical Global Impression Scale score at baseline and
after treatment with levetiracetam.
FIG. 2. Mean Yale Global Tic Severity Scale score at baseline and
after treatment with levetiracetam.
FIG. 3. Mean Tic Impairment Score at baseline and after treatment
with levetiracetam.
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The pathophysiology of TS is not fully elucidated, but
existing evidence suggests that disorders of the basal
ganglia play a role in this syndrome.7,9 Data showing that
the GABAergic areas of the basal ganglia are defective in
TS provide a rationale for the evaluation of drugs with
specific GABAergic effects.
Baclofen, for example, is an antispasticity drug that
contains both GABA and phenylethylamine moieties.7,22
Awaad studied baclofen (n  264) or botulinum toxin
type A (n  186) in patients age 18 years with tics or
TS (n  450 total).7 Treatment with baclofen or botuli-
num toxin type A was effective, safe, and reliable. In
responsive patients, the therapy produced dramatic re-
sults as determined by standard assessments of tics. The
most common side effects in the group treated with
baclofen were sedation and drowsiness. Soreness and
mild muscle weakness were the most commonly reported
adverse events in the group treated with botulinum toxin
A. A separate study, which evaluated baclofen in a small
number of patients (n  10) with tics, produced similar
results.22
The atypical GABAergic effects of levetiracetam pro-
vide the rationale for treatment of patients with
tics.11,12,23 By inhibition of zinc and beta carbolines in a
manner that interrupts chloride influx, levetiracetam may
enhance chloride ion influx at the GABA-A receptor
complex.
In this open-label study, the effect of levetiracetam on
motor and vocal tics was evaluated in a population of 60
pediatric patients with tics and TS. In addition, the ef-
fects of levetiracetam therapy on measures of behavior
and school performance were recorded. The results dem-
onstrate that treatment with levetiracetam improved clin-
ical outcomes in all 60 patients. A total of 43 patients
showed improvement in their behavior and school per-
formance. It must be noted that the interpretation of these
results is limited by the open-label study design. The
variability in symptoms of TS must also be considered
when interpreting results of clinical studies in these pa-
tients.
Levetiracetam may be a well-tolerated and relatively
safe alternative to currently used therapies.13–15 The most
commonly reported side effects associated with use of
levetiracetam are central nervous system effects, includ-
ing somnolence and fatigue. Reports of the use of leve-
tiracetam in children are limited,13,16–19,24 but behavioral
side effects have been reported.25,26 In some patients,
behavioral effects resolved with reductions in dosages or
discontinuation of therapy. Patients being treated with
levetiracetam should be monitored for such side effects,
and care should be taken with dose titration. Another
pharmacologic property of levetiracetam is the absence
of hepatic metabolism, which is associated with a very
low potential for drug interactions.14 This finding is an
important factor for patients who have coexisting condi-
tions, such as ADHD, that require use of an additional
medication.
Whenever drug therapy is used in children with tics, it
is important to monitor safety and tolerability as well as
efficacy. In addition, patients, family members, and
school personnel should be educated about the charac-
teristics of TS. Patients and their families can also benefit
from counseling and participation in support groups.
These preliminary results suggest that levetiracetam
may be useful in treating tics in children and adolescents.
Levetiracetam may be a candidate for additional evalu-
ations in patients who have both TS and epilepsy. The
established safety profile of levetiracetam makes this
drug an attractive alternative to other agents, which are
associated with the potential for serious side effects. In
addition, the low risk of drug interactions with levetirac-
etam might be a consideration for patients who require
the concurrent use of other medications to treat comorbid
conditions, such as ADHD.
Despite the limitations of the open-label study design,
the results presented here provide a rationale for initia-
tion of larger, double-blind, controlled studies of leveti-
racetam in children and adolescents. Although drugs are
studied in adults according to the guidelines established
by regulatory agencies, few drugs, including those to
treat tics and TS, have been adequately evaluated in
pediatric populations. In addition, other trials to more
fully elucidate the pathophysiology of TS could help lead
to targeted drug development and optimal drug therapy.
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